Clinical Trials with Immunotoxins

$0Z01FY2000BCNIH

Basic Sciences

Investigators

Linked publications & trials

Paper 18678888 Paper 18676854 Paper 18403491 Paper 17671130 Paper 17435179 Paper 17312057 Paper 17297371 Paper 16857795 Paper 16681430 Paper 16675574 Paper 16638849 Paper 16428485 Paper 16311729 Paper 16082249 Paper 16061911 Paper 15701286 Paper 15217923 Paper 14734446 Paper 14649883

Abstract

Phase I trials in patients with colon and breast cancer using the anti-LeY solid tumors with immunotoxin LMB-9 are being carried out by Dr. Lee Robert Kreitman. LMB-9 is a stable recombinant immunotoxin produced by genetic engineering. Dr. Robert Kreitman has completed a Phase I trial on leukemias and lymphomas with immunotoxin LMB-2 [anti-Tac(Fv)-PE38] that targets the alpha subunit of the IL2 receptor. In this trial, 1 complete response and many partial responses were observed. A Phase II trial is being planned. A clinical lot of an immunotoxin (BL22) that targets CD22 present on B-cell malignancies has been produced, and a Phase I trial is ongoing supervised by Dr. Kreitman. This immunotoxin has extremely good activity. Many complete responses have been observed in Hairy Cell Leukemia.

View original record on NIH RePORTER →